Investigating Chemotherapy Induced Peripheral Neuropathy in Ovarian Cancer Patients

Abstract

A woman’s risk of developing ovarian cancer in her lifetime is 1 in 78. Ovarian cancer is characterized by rapid cell growth in or around the ovaries that can compromise healthy tissues. Its subtle early symptoms often delay diagnosis until advanced stages. Chemotherapy, combined with surgery, is a common treatment approach. However, it introduces chemotherapy-induced peripheral neuropathy (CIPN). This neuropathy arises from chemotherapy's impact on peripheral nerves, resulting in sensations like tingling, burning, and weakness. CIPN has profound physical and psychological effects, affecting patients' daily lives and diminishing their quality of life (QoL). This article provides an in-depth exploration of ovarian cancer, its treatments, CIPN's mechanisms, diagnosis, management, and its impact on QoL based on research studies. Two studies highlight CIPN's prevalence among ovarian cancer patients and its detrimental effects on their QoL. Future directions in CIPN management emphasize patient-centered care and further research to alleviate this treatment-induced challenge.